Amikacin therapy for gram-negative septicemia

Meyer, Richard D.; Lewis, Robert P.; Finegold, Sydney M.

doi:10.1016/0002-9343(77)90663-5

Cited by 19 publications

(11 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the netilmicin group, 19 of the 36 evaluable patients (52.8%) had 30 total adverse reactions, including nephrotoxic- (Tables 3-5).…”

Section: Resultsmentioning

confidence: 99%

“…Two factors to consider are the risk of adverse reactions and the high prevalence of resistance to gentamicin noted in some institutions (18)(19)(20)23). Gentamicin and amikacin have been equally effective with susceptible pathogens and with no differences in toxicity in a double-blind study (27), but amikacin is considered for initial therapy where there is a significant risk of gentamicin resistance (18)(19)(20). Although active in vitro against many gentamicin-resistant bacilli, netilmicin is less active than amikacin against gentamicin-resistant P. aeruginosa and P. stuartii (4,17).…”

Section: Resultsmentioning

confidence: 99%

“…It is resistant to two of the enzymes that inactivate gentamicin (17,21) and has significantly less ototoxicity (19) and nephrotoxicity than gentamicin in experimental animals (7,13,15). In open clinical trials, it has been therapeutically effective and appears to have less cochlear toxicity than other aminoglycosides (2, 5; 11,12,16,22,29,30).…”

mentioning

confidence: 99%

“…In some clinical studies netilmicin has exhibited minimal nephrotoxicity (11,16), whereas in others nephrotoxicity has been appreciable (2,5,12,22,29,30). Amikacin is effective in therapy of patients with serious gram-negative infections, including those due to gentamicin-resistant organisms (18,19). It appears to have minimal nephrotoxicity (27,28) but somewhat more ototoxicity (18).…”

mentioning

confidence: 99%

“…The mean magnesium content of the broth was 0.28 mg/100 ml, and mean calcium content was 0.28 mg/100 ml. Organisms were considered resistant to gentamicin or netilmicin if the minimal inhibitory concentration (MIC) was 216 tLg/ ml and resistant to amikacin if the MIC was -32 ,ug/ ml (17,19,20 Nephrotoxicity was defined as an increase irq serum creatinine of >0.4 mg/100 ml if the base-line creatinine was <3.0 mg/100 ml and an increase of >0.9 mg/100 ml if the base-line creatinine was >3.0 mg/100 ml (27,28). If other factors were present such as shock, furosemide, congestive heart failure, other aminoglycosides, sulfonamides, or cephalosporins, the reaction was judged possible or doubtful.…”

mentioning

confidence: 99%

See 4 more Smart Citations

Prospective comparative study of efficacy and toxicity of netilmicin and amikacin

Bock¹,

Edelstein²,

Meyer³

1980

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Eighty patients were treated with either amikacin or netilmicin in a prospective randomized study of serious gram-negative bacillary infections, including 11 due to gentamicin-resistant pathogens. Thirty-six treated with netilmicin and 35 treated with amikacin were evaluable for efficacy or toxicity, or both. The overall groups differed significantly only in age. There were no significant differences in efficacy of the two drugs. There were no statistically significant differences at the 95% level between the netilmicin group and the amikacin group with respect to nephrotoxic reactions (38 versus 28%, respectively) or ototoxic reactions (9 versus 25%, respectively). Further comparative trials of netilmicin and other aminoglycosides appear warranted before it is widely used.

show abstract

“…In the netilmicin group, 19 of the 36 evaluable patients (52.8%) had 30 total adverse reactions, including nephrotoxic- (Tables 3-5).…”

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Prospective comparative study of efficacy and toxicity of netilmicin and amikacin

Bock¹,

Edelstein²,

Meyer³

1980

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

Gram-Negative Bacteremias

Lynch¹,

Hodges²,

Clark³

et al. 1981

Arch Intern Med

View full text Add to dashboard Cite

Serum Concentrations and Inhibitory Ratios During Amikacin Therapy of Gram‐Negative Infections

Farchione¹,

Chudzik²

1978

The Journal of Clinical Pharma

View full text Add to dashboard Cite

The ratio of the peak serum concentration after a 500-mg dose of amikacin to the pathogen minimum inhibitory concentration was determined for 95 patients under treatment for serious Gram-negative infections. There were 113 such ratios. The relationship of this inhibitory ratio to the clinical effectiveness and side effects of treatment with this new aminoglycoside was also studied. Mean peak serum concentration of drug was 25.8 microgram/ml, and mean inhibitory ratio was 13.0. Ninety-six per cent of inhibitory ratios were greater than or equal to 1.0. Therapy was rated totally effective in 85% of patients clinically evaluated and partially effective in 3%. Signs of renal or eighth cranial nerve impairment attributable to drug administration were confined to only two patients, and there were no other side effects. The reliability of amikacin therapy appears to be related to dependable serum levels and high inhibitory ratios.

show abstract

Amikacin therapy for gram-negative septicemia

Cited by 19 publications

References 18 publications

Prospective comparative study of efficacy and toxicity of netilmicin and amikacin

Prospective comparative study of efficacy and toxicity of netilmicin and amikacin

Gram-Negative Bacteremias

Serum Concentrations and Inhibitory Ratios During Amikacin Therapy of Gram‐Negative Infections

Contact Info

Product

Resources

About